{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:20:29Z","timestamp":1787566829715,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eclinm.2026.104106","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:58:55Z","timestamp":1784840335000},"page":"104106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative efficacy and safety of four long-acting granulocyte colony-stimulating factors for primary prophylaxis in patients with breast cancer: a prospective observational cohort study in China"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4076-9386","authenticated-orcid":false,"given":"Zihan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuohan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104106_bib1","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104106_bib2","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/2326-6066.CIR-13-0151","article-title":"The colony-stimulating factors and cancer","volume":"1","author":"Metcalf","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.eclinm.2026.104106_bib5","first-page":"525","article-title":"Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review","volume":"23","author":"Pfeil","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2019.07.95","article-title":"Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial","volume":"7","author":"Xu","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.eclinm.2026.104106_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1186\/s12885-024-12766-w","article-title":"Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or ewing sarcoma: a prospective, single-arm, pilot study","volume":"24","author":"Zhao","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib8","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-025-13736-6","article-title":"Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study","volume":"25","author":"Shi","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib9","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1186\/s12885-024-12892-5","article-title":"A randomized, multicenter phase III study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1186\/s12885-024-13148-y","article-title":"The efficacy and safety of the prophylactic application of PEG-rhG-CSF in radiotherapy with weekly concurrent chemotherapy for cervical cancer","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib11","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/03007995.2018.1495621","article-title":"Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged \u226565 years: a retrospective evaluation using Medicare claims","volume":"34","author":"Weycker","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.eclinm.2026.104106_bib12","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.2217\/fon-2022-0365","article-title":"Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy","volume":"18","author":"Kitchen","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.eclinm.2026.104106_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf415","article-title":"Safety and efficacy of same-day administration of eflapegrastim in patients with early-stage breast cancer receiving chemotherapy","volume":"31","author":"Modiano","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.eclinm.2026.104106_bib14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/1060028017706373","article-title":"Pegfilgrastim-induced bone pain: a review on incidence, risk factors, and evidence-based management","volume":"51","author":"Moore","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eclinm.2026.104106_bib15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2026.104106_bib16","first-page":"815","article-title":"Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts","volume":"28","author":"Kinoshita","year":"2001","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.eclinm.2026.104106_bib17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.104106_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/CM9.0000000000003445","article-title":"Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: a multicenter, randomized, phase 3 study","volume":"138","author":"Shi","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.eclinm.2026.104106_bib19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40265-023-01911-7","article-title":"Efbemalenograstim alfa: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.eclinm.2026.104106_bib20","first-page":"91","article-title":"Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial","volume":"32","author":"Glaspy","year":"2024","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib21","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.eclinm.2026.104106_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cllc.2015.12.002","article-title":"A randomized multicenter phase III study of single administration of mecapegfilgrastim (HHPG-19K), a pegfilgrastim biosimilar, for prophylaxis of chemotherapy-induced neutropenia in patients with advanced non-small-cell lung cancer (NSCLC)","volume":"17","author":"Zhou","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3816\/CBC.2003.n.003","article-title":"Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer","volume":"3","author":"Kubista","year":"2003","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib24","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104106_bib25","first-page":"34","article-title":"Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial","volume":"32","author":"Glaspy","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib26","volume":"2","author":"Glaspy","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.eclinm.2026.104106_bib27","first-page":"267","article-title":"Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies","volume":"24","author":"Bondarenko","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib28","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2217\/fon-2016-0016","article-title":"Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer","volume":"12","author":"Harbeck","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.eclinm.2026.104106_bib29","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","article-title":"The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)","volume":"89","author":"Lambertini","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eclinm.2026.104106_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1078155215585188","article-title":"Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients","volume":"22","author":"Pawloski","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.eclinm.2026.104106_bib31","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2011.37.8364","article-title":"Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base","volume":"30","author":"Kirshner","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104106_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.20636","article-title":"Empiric dose reduction of pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy","volume":"26","author":"Paba","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104106_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40780-022-00272-9","article-title":"Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience","volume":"9","author":"Tsuboi","year":"2023","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.eclinm.2026.104106_bib34","first-page":"723","article-title":"Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim","volume":"24","author":"Xu","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eclinm.2026.104106_bib35","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1097\/j.pain.0000000000000294","article-title":"Assessment of musculoskeletal pain sensitivity and temporal summation by cuff pressure algometry: a reliability study","volume":"156","author":"Graven-Nielsen","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.eclinm.2026.104106_bib36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41413-023-00280-x","article-title":"Low back pain and osteoarthritis pain: a perspective of estrogen","volume":"11","author":"Pang","year":"2023","journal-title":"Bone Res"},{"key":"10.1016\/j.eclinm.2026.104106_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaf081","article-title":"REaCT-5G: a randomized trial of bone pain with 5-day filgrastim vs pegfilgrastim for neutropenia in breast cancer","volume":"9","author":"Ng","year":"2025","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.eclinm.2026.104106_bib38","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/ANNALS-25-02600","article-title":"Timing of pegfilgrastim administration and pegfilgrastim-induced bone pain: a prospective, randomized phase 3 trial","volume":"179","author":"Li","year":"2026","journal-title":"Ann Intern Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:30:43Z","timestamp":1787560243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026003597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S2589537026003597"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104106","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of four long-acting granulocyte colony-stimulating factors for primary prophylaxis in patients with breast cancer: a prospective observational cohort study in China","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104106"}}